NCT05732051View on ClinicalTrials.gov

Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 16, 2023

Primary Completion Date

August 1, 2025

Study Completion Date

September 30, 2035

Conditions
Breast CancerMetastatic Breast CancerCancer Therapy-Related Cardiac DysfunctionCardiotoxicityHeart Failure
Interventions
DIETARY_SUPPLEMENT

Nicotinamide Riboside

Nicotinamide Riboside 500mg b.i.d as long as the patient is receiving anthracycline therapy

DIETARY_SUPPLEMENT

Placebo

Matching placebo b.i.d as long as the patient is receiving anthracycline therapy

Trial Locations (1)

1478

RECRUITING

Akershus University Hospital, Lørenskog

All Listed Sponsors
collaborator

ChromaDex, Inc.

INDUSTRY

collaborator

Norwegian Cancer Society

OTHER

collaborator

Norwegian Breast Cancer Association

UNKNOWN

collaborator

Helse Sor-Ost

OTHER_GOV

lead

University Hospital, Akershus

OTHER